<!DOCTYPE html>
<html lang="en" dir="auto">

<head>
<head>
    <title>cardiovascular medicine</title>
    <meta charset="utf-8">
    <meta name="description"
        content="Website meta description for google search results go here" />
    <meta name="dc.relation" content="https://trxiv.yorks0n.com" />
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="theme-color" content="#1A94D2" />

    

    
    
    
    <link rel="stylesheet" href="/css/main.min.css" media="screen">

</head>


<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<meta name="robots" content="index, follow">
<title>cardiovascular medicine | TRxiv2</title>
<meta name="keywords" content="">
<meta name="description" content="Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease
Authors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A.">
<meta name="author" content="">
<link rel="canonical" href="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/">
<link crossorigin="anonymous" href="/assets/css/stylesheet.904bd1e751cdd2a584fa6bed3fa1166dfd8ec9949ebfd0c4d69c5add5e17c23d.css" integrity="sha256-kEvR51HN0qWE&#43;mvtP6EWbf2OyZSev9DE1pxa3V4Xwj0=" rel="preload stylesheet" as="style">
<script defer crossorigin="anonymous" src="/assets/js/highlight.f413e19d0714851f6474e7ee9632408e58ac146fbdbe62747134bea2fa3415e0.js" integrity="sha256-9BPhnQcUhR9kdOfuljJAjlisFG&#43;9vmJ0cTS&#43;ovo0FeA="
    onload="hljs.initHighlightingOnLoad();"></script>
<link rel="icon" href="https://trxiv.yorks0n.com/favicon.ico">
<link rel="icon" type="image/png" sizes="16x16" href="https://trxiv.yorks0n.com/favicon-16x16.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://trxiv.yorks0n.com/favicon-32x32.png">
<link rel="apple-touch-icon" href="https://trxiv.yorks0n.com/apple-touch-icon.png">
<link rel="mask-icon" href="https://trxiv.yorks0n.com/safari-pinned-tab.svg">
<meta name="theme-color" content="#2e2e33">
<meta name="msapplication-TileColor" content="#2e2e33">
<noscript>
    <style>
        #theme-toggle,
        .top-link {
            display: none;
        }

    </style>
    <style>
        @media (prefers-color-scheme: dark) {
            :root {
                --theme: rgb(29, 30, 32);
                --entry: rgb(46, 46, 51);
                --primary: rgb(218, 218, 219);
                --secondary: rgb(155, 156, 157);
                --tertiary: rgb(65, 66, 68);
                --content: rgb(196, 196, 197);
                --hljs-bg: rgb(46, 46, 51);
                --code-bg: rgb(55, 56, 62);
                --border: rgb(51, 51, 51);
            }

            .list {
                background: var(--theme);
            }

            .list:not(.dark)::-webkit-scrollbar-track {
                background: 0 0;
            }

            .list:not(.dark)::-webkit-scrollbar-thumb {
                border-color: var(--theme);
            }
        }

    </style>
</noscript><meta property="og:title" content="cardiovascular medicine" />
<meta property="og:description" content="Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease
Authors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A." />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://trxiv.yorks0n.com/posts/cardiovascular-medicine/" /><meta property="article:section" content="posts" />
<meta property="article:published_time" content="2023-09-13T10:39:03+00:00" />
<meta property="article:modified_time" content="2023-09-13T10:39:03+00:00" />

<meta name="twitter:card" content="summary"/>
<meta name="twitter:title" content="cardiovascular medicine"/>
<meta name="twitter:description" content="Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease
Authors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A."/>


<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [, 
    {
      "@type": "ListItem",
      "position":  2 ,
      "name": "Posts",
      "item": "https://trxiv.yorks0n.com/posts/"
    }, 
    {
      "@type": "ListItem",
      "position":  3 ,
      "name": "cardiovascular medicine",
      "item": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
    }
  ]
}
</script>
<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "BlogPosting",
  "headline": "cardiovascular medicine",
  "name": "cardiovascular medicine",
  "description": "Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease\nAuthors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A.",
  "keywords": [
    
  ],
  "articleBody": " Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease\nAuthors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A.; Andreassen, O. A.; Sullivan, P. F.; Lu, Y.; Fang, F.\nScore: 8.1, Published: 2023-09-01 DOI: 10.1101/2023.09.01.23294931\nMajor depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in excess morbidity and mortality. Using genetic data, this study elucidates biological mechanisms, key risk factors, and causal pathways underlying the comorbidity. We show that CVDs share a large proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of the shared genetic liability between MDD and CVD revealed seven novel loci and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial risk factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not vice versa, and demonstrated that the causal effects are partly explained by metabolic and psychosocial factors. The distinct signature of MDD-CVD comorbidity aligns with the idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD. In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well as key modifiable risk factors for prevention of CVD in individuals with MDD.\nAORTA Gene: Polygenic prediction improves detection of thoracic aortic aneurysm\nAuthors: Pirruccello, J. P.; Khurshid, S.; Lin, H.; Weng, L.-C.; Zamirpour, S.; Kany, S.; Raghavan, A.; Koyama, S.; Vasan, R. S.; Benjamin, E. J.; Lindsay, M. E.; Ellinor, P. T.\nScore: 1.5, Published: 2023-08-25 DOI: 10.1101/2023.08.23.23294513\nBackgroundThoracic aortic disease is an important cause of morbidity and mortality in the US, and aortic diameter is a heritable contributor to risk. Could a polygenic prediction of ascending aortic diameter improve detection of aortic aneurysm? MethodsDeep learning was used to measure ascending thoracic aortic diameter in 49,939 UK Biobank participants. A genome-wide association study (GWAS) was conducted in 39,524 participants and leveraged to build a 1.1 million-variant polygenic score with PRScs-auto. Aortic diameter prediction models were built with the polygenic score (\"AORTA Gene\") and without it. The models were tested in a held-out set of 4,962 UK Biobank participants and externally validated in 5,469 participants from Mass General Brigham Biobank (MGB), 1,298 from the Framingham Heart Study (FHS), and 610 participants from All of Us. ResultsIn each test set, the AORTA Gene model explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.9% (95% CI 37.8-42.0%) vs 29.2% (95% CI 27.1-31.4%) in UK Biobank, 36.5% (95% CI 34.4-38.5%) vs 32.5% (95% CI 30.4-34.5%) in MGB, 41.8% (95% CI 37.7-45.9%) vs 33.0% (95% CI 28.9-37.2%) in FHS, and 34.9% (95% CI 28.8-41.0%) vs 28.9% (95% CI 22.9-35.0%) in All of Us. AORTA Gene had a greater AUROC for identifying diameter [\u0026ge;]4cm in each test set: 0.834 vs 0.765 (P=7.3E-10) in UK Biobank, 0.808 vs 0.767 in MGB (P=4.5E-12), 0.856 vs 0.818 in FHS (P=8.5E-05), and 0.827 vs 0.791 (P=7.8E-03) in All of Us. ConclusionsGenetic information improved estimation of thoracic aortic diameter when added to clinical risk factors. Larger and more diverse cohorts will be needed to develop more powerful and equitable scores.\nSevere biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids.\nAuthors: Abdullah, R.; Bjornebekk, A. K.; Hauger, L. E.; Hullstein, I. R.; Edvardsen, T.; Haugaa, K. I. H. H.; Almaas, V. M.\nScore: 1.0, Published: 2023-09-06 DOI: 10.1101/2023.09.06.23295123\nAimsExplore the cardiovascular effects of long-term anabolic-androgenic steroid (AAS)-use in both current and former weightlifting AAS-users, and estimate the occurrence of severe reduced myocardial function and the impact of duration and amount of AAS. MethodsIn this cross-sectional study 101 weightlifting AAS-users with at least one year cumulative AAS-use (mean 11{+/-}7 accumulated years of AAS-use) were compared to 71 non-using weightlifting controls (WLC) using clinical data and echocardiography. ResultsSixty-nine were current, 30 former (\u003e 1 year since quitted), and 2 AAS-users were not available for this classification. AAS-users had higher left ventricular mass index (LVMI) (106{+/-}26 versus 80{+/-}15 g/m2, P\u003c0.001), worse LV ejection fraction (LVEF) (49{+/-}7 versus 59{+/-}5%, P\u003c0.001) and right ventricular global longitudinal strain (RVGLS) (-17.3{+/-}3.5 versus -22.8{+/-}2.0%, P\u003c0.001), and higher systolic blood pressure (SBP) (141{+/-}17 vs. 133{+/-}11 mmHg, p\u003c0.001) compared with WLC. In current users accumulated duration of AAS-use was 12{+/-}7 years, and in former 9{+/-}6 years (quitted 6{+/-}6 years earlier). Compared to WLC, LVMI and LVEF were pathological in current and former users (p\u003c0.05) with equal distribution of severely reduced myocardial function (LVEF [\u0026le;]40%) (11% vs. 10%, NS). In current users estimated life time AAS-dose correlated with reduced LVEF and LVGLS, p\u003c0.05, but not with LVMI, p=0.12. Regression analyses of the total population showed that the strongest determinant of reduced LVEF were not coexisting strength training or hypertension, but history of AAS-use ({beta} -0.53, P\u003c0.001). ConclusionsLong-term AAS-users showed severely biventricular cardiomyopathy. The reduced systolic function was also found upon discountied use.\n",
  "wordCount" : "861",
  "inLanguage": "en",
  "datePublished": "2023-09-13T10:39:03Z",
  "dateModified": "2023-09-13T10:39:03Z",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://trxiv.yorks0n.com/posts/cardiovascular-medicine/"
  },
  "publisher": {
    "@type": "Organization",
    "name": "TRxiv2",
    "logo": {
      "@type": "ImageObject",
      "url": "https://trxiv.yorks0n.com/favicon.ico"
    }
  }
}
</script>
</head>

<body class="" id="top">
<script>
    if (localStorage.getItem("pref-theme") === "dark") {
        document.body.classList.add('dark');
    } else if (localStorage.getItem("pref-theme") === "light") {
        document.body.classList.remove('dark')
    } else if (window.matchMedia('(prefers-color-scheme: dark)').matches) {
        document.body.classList.add('dark');
    }

</script>

<header class="header">
    <nav class="nav">
        <div class="logo">
            <a href="https://trxiv.yorks0n.com" accesskey="h" title="TRxiv2 (Alt + H)">TRxiv2</a>
            <div class="logo-switches">
                <button id="theme-toggle" accesskey="t" title="(Alt + T)">
                    <svg id="moon" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <path d="M21 12.79A9 9 0 1 1 11.21 3 7 7 0 0 0 21 12.79z"></path>
                    </svg>
                    <svg id="sun" xmlns="http://www.w3.org/2000/svg" width="24" height="18" viewBox="0 0 24 24"
                        fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round"
                        stroke-linejoin="round">
                        <circle cx="12" cy="12" r="5"></circle>
                        <line x1="12" y1="1" x2="12" y2="3"></line>
                        <line x1="12" y1="21" x2="12" y2="23"></line>
                        <line x1="4.22" y1="4.22" x2="5.64" y2="5.64"></line>
                        <line x1="18.36" y1="18.36" x2="19.78" y2="19.78"></line>
                        <line x1="1" y1="12" x2="3" y2="12"></line>
                        <line x1="21" y1="12" x2="23" y2="12"></line>
                        <line x1="4.22" y1="19.78" x2="5.64" y2="18.36"></line>
                        <line x1="18.36" y1="5.64" x2="19.78" y2="4.22"></line>
                    </svg>
                </button>
            </div>
        </div>
        <ul id="menu">
        </ul>
    </nav>
</header>
<main class="main">
<article class="post-single">
  <header class="post-header">
    
    <h1 class="post-title">
      cardiovascular medicine
    </h1>
    <div class="post-meta"><span>updated on September 13, 2023</span>

</div>
  </header> 
  <div class="post-content"><div class="accordion accordion-flush" id="accordionFlushExample"><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.01.23294931">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.01.23294931" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.01.23294931">
        <p class="paperTitle">Distinct biological signature and modifiable risk factors underly the comorbidity between major depressive disorder and cardiovascular disease</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.01.23294931" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.01.23294931" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Bergstedt, J.; Pasman, J. A.; Ma, Z.; Harder, A.; Yao, S.; Parker, N.; Treur, J. L.; Smit, D. J. A.; Frei, O.; Shadrin, A.; Meijsen, J. J.; Shen, Q.; Tornvall, P.; Buil, A.; Werge, T.; Hjerling-Leffler, J.; Als, T. D.; Borglum, A. D.; Lewis, C. M.; McIntosh, A. M.; Valdimarsdottir, U. A.; Andreassen, O. A.; Sullivan, P. F.; Lu, Y.; Fang, F.</p>
        <p class="info">Score: 8.1, Published: 2023-09-01 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.01.23294931' target='https://doi.org/10.1101/2023.09.01.23294931'> 10.1101/2023.09.01.23294931</a></p>
        <p class="abstract">Major depressive disorder (MDD) and cardiovascular disease (CVD) are often comorbid, resulting in excess morbidity and mortality. Using genetic data, this study elucidates biological mechanisms, key risk factors, and causal pathways underlying the comorbidity. We show that CVDs share a large proportion of their genetic risk factors with MDD. Multivariate genome-wide association analysis of the shared genetic liability between MDD and CVD revealed seven novel loci and distinct patterns of tissue and brain cell-type enrichments, suggesting a role for the thalamus. Part of the genetic overlap was explained by shared inflammatory, metabolic, and psychosocial risk factors. Finally, we found support for causal effects of genetic liability to MDD on CVD risk, but not vice versa, and demonstrated that the causal effects are partly explained by metabolic and psychosocial factors. The distinct signature of MDD-CVD comorbidity aligns with the idea of an immunometabolic sub-type of MDD more strongly associated with CVD than overall MDD. In summary, we identify plausible biological mechanisms underlying MDD-CVD comorbidity, as well as key modifiable risk factors for prevention of CVD in individuals with MDD.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.08.23.23294513">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.08.23.23294513" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.08.23.23294513">
        <p class="paperTitle">AORTA Gene: Polygenic prediction improves detection of thoracic aortic aneurysm</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.08.23.23294513" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.08.23.23294513" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Pirruccello, J. P.; Khurshid, S.; Lin, H.; Weng, L.-C.; Zamirpour, S.; Kany, S.; Raghavan, A.; Koyama, S.; Vasan, R. S.; Benjamin, E. J.; Lindsay, M. E.; Ellinor, P. T.</p>
        <p class="info">Score: 1.5, Published: 2023-08-25 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.08.23.23294513' target='https://doi.org/10.1101/2023.08.23.23294513'> 10.1101/2023.08.23.23294513</a></p>
        <p class="abstract">BackgroundThoracic aortic disease is an important cause of morbidity and mortality in the US, and aortic diameter is a heritable contributor to risk. Could a polygenic prediction of ascending aortic diameter improve detection of aortic aneurysm?

MethodsDeep learning was used to measure ascending thoracic aortic diameter in 49,939 UK Biobank participants. A genome-wide association study (GWAS) was conducted in 39,524 participants and leveraged to build a 1.1 million-variant polygenic score with PRScs-auto. Aortic diameter prediction models were built with the polygenic score (&#34;AORTA Gene&#34;) and without it. The models were tested in a held-out set of 4,962 UK Biobank participants and externally validated in 5,469 participants from Mass General Brigham Biobank (MGB), 1,298 from the Framingham Heart Study (FHS), and 610 participants from All of Us.

ResultsIn each test set, the AORTA Gene model explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.9% (95% CI 37.8-42.0%) vs 29.2% (95% CI 27.1-31.4%) in UK Biobank, 36.5% (95% CI 34.4-38.5%) vs 32.5% (95% CI 30.4-34.5%) in MGB, 41.8% (95% CI 37.7-45.9%) vs 33.0% (95% CI 28.9-37.2%) in FHS, and 34.9% (95% CI 28.8-41.0%) vs 28.9% (95% CI 22.9-35.0%) in All of Us. AORTA Gene had a greater AUROC for identifying diameter [&amp;ge;]4cm in each test set: 0.834 vs 0.765 (P=7.3E-10) in UK Biobank, 0.808 vs 0.767 in MGB (P=4.5E-12), 0.856 vs 0.818 in FHS (P=8.5E-05), and 0.827 vs 0.791 (P=7.8E-03) in All of Us.

ConclusionsGenetic information improved estimation of thoracic aortic diameter when added to clinical risk factors. Larger and more diverse cohorts will be needed to develop more powerful and equitable scores.</p>
      </div>
    </div>
  </div><div class="accordion-item">
    <h3 class="accordion-header" id="flush-heading10.1101/2023.09.06.23295123">
      <button class="accordion-button collapsed" type="button" data-bs-toggle="collapse" data-bs-target="#flush-collapse10.1101/2023.09.06.23295123" aria-expanded="false" aria-controls="flush-collapse10.1101/2023.09.06.23295123">
        <p class="paperTitle">Severe biventricular cardiomyopathy in both current and former long-term users of anabolic-androgenic steroids.</p>
      </button>
    </h3>
    <div id="flush-collapse10.1101/2023.09.06.23295123" class="accordion-collapse collapse" aria-labelledby="flush-heading10.1101/2023.09.06.23295123" data-bs-parent="#accordionFlushExample">
      <div class="accordion-body">
        <p class="author">Authors: Abdullah, R.; Bjornebekk, A. K.; Hauger, L. E.; Hullstein, I. R.; Edvardsen, T.; Haugaa, K. I. H. H.; Almaas, V. M.</p>
        <p class="info">Score: 1.0, Published: 2023-09-06 </p>
        <p class="info">DOI: <a href='https://doi.org/10.1101/2023.09.06.23295123' target='https://doi.org/10.1101/2023.09.06.23295123'> 10.1101/2023.09.06.23295123</a></p>
        <p class="abstract">AimsExplore the cardiovascular effects of long-term anabolic-androgenic steroid (AAS)-use in both current and former weightlifting AAS-users, and estimate the occurrence of severe reduced myocardial function and the impact of duration and amount of AAS.

MethodsIn this cross-sectional study 101 weightlifting AAS-users with at least one year cumulative AAS-use (mean 11{&#43;/-}7 accumulated years of AAS-use) were compared to 71 non-using weightlifting controls (WLC) using clinical data and echocardiography.

ResultsSixty-nine were current, 30 former (&gt; 1 year since quitted), and 2 AAS-users were not available for this classification. AAS-users had higher left ventricular mass index (LVMI) (106{&#43;/-}26 versus 80{&#43;/-}15 g/m2, P&lt;0.001), worse LV ejection fraction (LVEF) (49{&#43;/-}7 versus 59{&#43;/-}5%, P&lt;0.001) and right ventricular global longitudinal strain (RVGLS) (-17.3{&#43;/-}3.5 versus -22.8{&#43;/-}2.0%, P&lt;0.001), and higher systolic blood pressure (SBP) (141{&#43;/-}17 vs. 133{&#43;/-}11 mmHg, p&lt;0.001) compared with WLC. In current users accumulated duration of AAS-use was 12{&#43;/-}7 years, and in former 9{&#43;/-}6 years (quitted 6{&#43;/-}6 years earlier). Compared to WLC, LVMI and LVEF were pathological in current and former users (p&lt;0.05) with equal distribution of severely reduced myocardial function (LVEF [&amp;le;]40%) (11% vs. 10%, NS). In current users estimated life time AAS-dose correlated with reduced LVEF and LVGLS, p&lt;0.05, but not with LVMI, p=0.12. Regression analyses of the total population showed that the strongest determinant of reduced LVEF were not coexisting strength training or hypertension, but history of AAS-use ({beta} -0.53, P&lt;0.001).

ConclusionsLong-term AAS-users showed severely biventricular cardiomyopathy. The reduced systolic function was also found upon discountied use.</p>
      </div>
    </div>
  </div>
</div>









<script src="/js/bundle.min.js" defer></script>



  </div>

  <footer class="post-footer">
    <ul class="post-tags">
    </ul>
  </footer>
</article>
    </main>
    
<footer class="footer">
    <span>&copy; 2023 <a href="https://trxiv.yorks0n.com">TRxiv2</a></span>
    <span>
        Â· Made by Yorkson
    </span>
</footer>
<a href="#top" aria-label="go to top" title="Go to Top (Alt + G)" class="top-link" id="top-link" accesskey="g">
    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 12 6" fill="currentColor">
        <path d="M12 6H0l6-6z" />
    </svg>
</a>

<script>
    let menu = document.getElementById('menu')
    if (menu) {
        menu.scrollLeft = localStorage.getItem("menu-scroll-position");
        menu.onscroll = function () {
            localStorage.setItem("menu-scroll-position", menu.scrollLeft);
        }
    }

    document.querySelectorAll('a[href^="#"]').forEach(anchor => {
        anchor.addEventListener("click", function (e) {
            e.preventDefault();
            var id = this.getAttribute("href").substr(1);
            if (!window.matchMedia('(prefers-reduced-motion: reduce)').matches) {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView({
                    behavior: "smooth"
                });
            } else {
                document.querySelector(`[id='${decodeURIComponent(id)}']`).scrollIntoView();
            }
            if (id === "top") {
                history.replaceState(null, null, " ");
            } else {
                history.pushState(null, null, `#${id}`);
            }
        });
    });

</script>
<script>
    var mybutton = document.getElementById("top-link");
    window.onscroll = function () {
        if (document.body.scrollTop > 800 || document.documentElement.scrollTop > 800) {
            mybutton.style.visibility = "visible";
            mybutton.style.opacity = "1";
        } else {
            mybutton.style.visibility = "hidden";
            mybutton.style.opacity = "0";
        }
    };

</script>
<script>
    document.getElementById("theme-toggle").addEventListener("click", () => {
        if (document.body.className.includes("dark")) {
            document.body.classList.remove('dark');
            localStorage.setItem("pref-theme", 'light');
        } else {
            document.body.classList.add('dark');
            localStorage.setItem("pref-theme", 'dark');
        }
    })

</script>
</body>

</html>
